Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab + Carboplatin in CCR5+ mTNBC
NCT03838367Phase 2Terminated
- Sponsor
- CytoDyn Inc.
- Start
- Apr 2019
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of leronlimab in triple-negative breast cancer (TNBC), sponsored by CytoDyn Inc.. Started Apr 2019; status: terminated.
02
Drugs
leronlimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03838367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838367.